The pharmacology of CGS 25462: a potent, orally bioavailable, long‐acting inhibitor of neutral endopeptidase 24.11

@article{Trapani1993ThePO,
  title={The pharmacology of CGS 25462: a potent, orally bioavailable, long‐acting inhibitor of neutral endopeptidase 24.11},
  author={A. Trapani and S. D. Lombaert and M. Erion and R. Ghai and J. Peppard and R. Lappe and M. Worcel},
  journal={Journal of Hypertension},
  year={1993},
  volume={11},
  pages={S220–S221}
}
4 Citations
Effects of combined AT recep
  • 2008
Dual angiotensin-converting enzyme/neutral endopeptidase inhibition on cardiac and renal fibrosis and inflammation in DOCA-salt hypertensive rats
TLDR
Dual ACE/NEP inhibition was more effective than ACE or NEP inhibition in decreasing inflammatory mediators, and improving cardiac and renal fibrosis in deoxycorticosterone acetate-salt hypertensive rats, suggesting a role for NEP inhibited added to blockade of the renin-angiotensin system that may explain the greater efficacy of omapatrilat. Expand
Comparison of angiotensin-converting enzyme (ACE), neutral endopeptidase (NEP) and dual ACE/NEP inhibition on blood pressure and resistance arteries of deoxycorticosterone acetate-salt hypertensive rats
TLDR
Dual inhibition of ACE/NEP in DOCA-salt hypertensive rats resulted in potent anti-hypertensive effects, prevented vascular remodelling and improved endothelial function of resistance arteries, which may confer protection against end-organ damage characteristic of severe hypertension. Expand
Improved passive oral drug delivery via prodrugs
Abstract Employing prodrugs to improve drug delivery and oral absorption, in particular, is a proven strategy. This review describes recent examples of prodrugs intended to improve oral deliveryExpand